Overview

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

This phase II randomised, double blind, placebo controlled, multicentre trial is designed to assess the efficacy and safety of continuous icotinib plus chemotherapy versus chemotherapy alone in patients who have progressed after benefiting from previous second or third-line icotinib treatment (more than 6 months) in locally advanced or metastatic non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.

Treatments:

Docetaxel
Pemetrexed